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as superior to the more simple methods for detecting non-
responders [3], and a further search for better prognostic 
markers is needed.
Versteeg et al. present the predictive value of pre-implant 
patient-reported health status on mortality using the Kansas 
City Cardiomyopathy Questionnaire (KCCQ) in a single-
centre cohort of patients receiving CRT [4]. This well-
conducted study demonstrated that a poor health status 
at baseline, defined as a KCCQ score of < 50 out of 100 
points, was associated with a 2.5-fold increase in the com-
bined endpoint of all-cause mortality or hospitalisation in 
a cardiology department during four years of follow-up. 
Furthermore, a poor health status was associated with a 
threefold increase in amount of days spent in hospital. The 
patient-reported health status was a stronger predictor than 
traditional baseline characteristics previously shown to have 
an impact on clinical outcome in CRT patients including 
renal dysfunction, New York Heart Association (NYHA) 
functional class, and male gender. With this comprehensive 
evaluation of the patients’ perception of their disease, the 
authors have brought focus on a very important aspect of 
patient care in CRT that is often overlooked. Commonly, 
physicians focus more on ‘objective’ technical measures or 
on how they interpret the patients’ health status.
This study indicates that the KCCQ may be an impor-
tant tool to identify CRT candidates with a higher risk of 
adverse outcome. These patients may potentially benefit 
from more intensive follow-up including remote monitor-
ing after implantation. The results of this study support 
inclusion of the KCCQ or other patient-reported outcomes 
in future observational and interventional studies in heart 
failure patients and patients with implanted cardiac devices 
[5]. Furthermore, since improvement in self-reported health 
status after implantation of a CRT device has been found to 
be associated with increased survival [6], the KCCQ might 
Cardiac resynchronisation therapy (CRT) improves survival 
and reduces symptoms in patients with drug refractory heart 
failure and bundle branch block, and has been implemented 
into international guidelines over the last decade [1]. 
Despite the fact that several large randomised studies have 
demonstrated CRT to be very efficient, around 30–50 % of 
the patients receiving CRT – depending on what outcome 
is measured – do not benefit from this treatment strategy. 
These patients are often referred to as non-responders.
Potential candidates for CRT include some of the most 
severely symptomatic heart patients who have a poor prog-
nosis and often multiple comorbidity including ischaemic 
heart disease, renal dysfunction, diabetes, and chronic 
obstructive pulmonary disorder. Although the success rate 
of establishing CRT has improved markedly, the risk of 
complications is still significantly higher than for other car-
diac implantable electronic devices, which has to be taken 
into account in this fragile population [2]. As a consequence 
of that, a number of studies have focused on identifying 
baseline factors predicting which patients can expect to 
benefit from CRT to select the most appropriate candidates. 
These prognostic variables range from advanced cardiac 
imaging or invasive measurements, often expensive and 
time consuming acquiring highly specialised equipment and 
expertise, to more simple, inexpensive, and readily avail-
able information at every centre, such as baseline comorbid-
ity and the standard 12-lead electrocardiogram. So far, none 
of the advanced measures have been generally accepted 
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potentially also be a more relevant and more sensitive end-
point than echocardiographic parameters or NYHA classifi-
cation when testing new strategies within the field of CRT. It 
is important not to focus only on length of survival but also 
on improvement of patient-reported outcomes and quality 
of life.
The sample size in the study by Versteeg et al. was mod-
erate, and the confidence intervals wide. Therefore, before 
implementing these new tools in daily clinical practice the 
prognostic value of self-reported health scores should be 
confirmed in larger multicentre cohort studies with long fol-
low-up to increase the power of the estimates and to allow 
more variables in the analyses, which would minimise the 
risk of residual confounding. Randomised controlled trials 
should be awaited before implementing new follow-up or 
treatment regimens for these patients with lower KCCQ 
scores. It would also be interesting to investigate how 
changes in the KCCQ score affect long-term outcome and 
whether any intervention that improves the patient-reported 
health status without directly altering the heart failure 
therapy – such as psychological training to cope better with 
a chronic disease – has any impact on long-term outcome in 
these patients.
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